| Assessment Status | Rapid review complete |
| HTA ID | - |
| Drug | Daclizumab |
| Brand | Zinbryta® |
| Indication | Indicated in adult patients for the treatment of relapsing forms of multiple sclerosis. |
| Assessment Process | |
| Rapid review commissioned | 26/09/2016 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended at the Submitted Price |
The HSE has approved reimbursement following confidential price negotiations.
7/03/2018 – The European Medicines Agency (EMA) has recommended the immediate suspension and recall of daclizumab.